甲状腺疾病患者血清可溶性细胞间粘附分子-1的研究  

A study of soluble intercellular adhesion molecule-1 in sera of patients with thyroid diseases

作　　者：刘金泉[1] 方佩华[2] 冯凭[1] 李宁[2] 孟召伟[2] 吕枚[2] 许静[2] 

机构地区：[1]天津医科大学总医院代谢科,300052 [2]天津医科大学总医院核医学科,300052

出　　处：《中华核医学杂志》2008年第4期264-266,共3页Chinese Journal of Nuclear Medicine

摘　　要：目的探讨血清可溶性细胞间粘附分子-1（SICAM-1）水平与甲状腺疾病的关系。方法采用^125Ⅰ-sICAM-1 RIA方法，检测了健康人273名（对照组），Graves（GD）病患者557例，初诊慢性淋巴细胞性甲状腺炎（HT）患者33例，初诊单纯性甲状腺肿（SG）患者17例，初诊非毒性结节性甲状腺肿（NTNG）患者9例的血清sICAM-1水平，比较各组间差异及其与其他指标的相关性。变量资料为正态分布时，应用ANOVA或t检验进行组间比较；不满足条件时，应用秩和检验（Kruskal-Wallis或Mann-Whitney）进行分析。结果初诊GD组[58例，（255．04±82．40）ug/L]和HT组[（227．22±77．08）ug／L]sICAM-1水平均高于对照组[（149．89±39、45）-L]（GD：Z=-9．401，HT：Z=-5．902；P均〈0．01），而SG组[（173．82±59．50）ug/L]和NTNG组[（159．31±28．73）ug/L]与对照组差别无统计学意义（SG：Z=-1．9，NTNG：Z=-0．949；P均〉0．05）。初诊及各治疗阶段GD伴突眼组sICAM-1水平均高于非突眼组，但仅在治疗≥19个月组差异有统计学意义[（211．58±53．58）与（189．50±39．99）ug/L；t=2．004，P〈0．05]。复发GD突眼及非突眼组sICAM-1水平亦显著高于对照组（X^2=88．257，P〈0．01）。在经抗甲状腺药物（ATD）治疗后甲状腺功能恢复正常且病情稳定的GD患者中，sICAM-1水平随疗程延长逐步缓慢降低，且当疗程≥19个月时，GD组在非突眼及突眼患者中，其血清sICAM-1[（189．50±39．99），（211．58±53．58）ug/L]与各自初诊组[（244．75±81．58），（287．36±79．20）ug/L]差异有统计学意义（F=9．986和3．398，P〈0．01和P〈0．05），但直至停药时仍高于对照组[（185．25±39．64）与（149．89±39．45）ug/L；Z=-3．813，P〈0．05]。结论血清sICAM-1可反映自身免疫性甲状腺疾病（AITD）患者体内的自身免疫状态，其测定对GD、HT有辅助诊断价值，这对于了解GD患者的�Objective Markedly elevated serum soluble intercelhdar adhesion molecule 1 （sICAM-1） level has recently been reported in patients with autoimmune thyroid disease （ARID）. The aim of this study was to investigate the clinical significance of slCAM-1 serum level in patients with different thyroid diseases. Metbors A total of 616 patients were recruited, consisting of 557 Graves＇ disease （GD）, 33 untreated Hashimoto＇s thyroiditis （HT）, 17 untreated simple goiter （SG） and 9 nontoxic nodular goiter （NTNG）. Control was a group of 273 healthy individuals with no prior history of thyroid disease. Their serum sICAM-1 levels were measured by ^125Ⅰ-slCAM-1 radioimmunoassay. If sICAM-1 levels of every group fit normal distribution, statistical difference was calculated by ANOVA or t-test; if not, then rank sum test （ Kruskal-Wallis or Mann-Whitney） was used. Results There was no statistically significant difference among the SG [ （ 173. 82 ±59. 50） ug/L], NTNG [ （ 159.31±28.73） ug/L] and control [ （ 149.89 ±39.45） ug/L] groups; whereas the levels in both untreated GD [ （255.04 ±82.40）ug/L] and HT [ （227.22 ±77.08） ug/L] groups were elevated and statistically significant by comparison with the control group （Z = -9.401, -5. 902, respectively; both with P 〈 0.01 ）. In each stage of antithyroid drugs （ATD） treatment, the serum sICAM-1 concentrations of GD patients with ophthalmopathy were higher than those without ophthalmopathy, however, only the group with ATD duration ≥19 months was found significant （t =2. 004, P 〈0.05）. The recurrent GD group had higher slCAM-1 levels than control group （X^2= 88. 257, P 〈0.01 ）. In stable euthyroid patients receiving ATD, a steady trend of gradual decline in slCAM-1 levels was found. When ATD treatment lasted ≥19 months, the slCAM-1 levels in GD patients with and without ophthalmopathy [ （211.58 ±53.58） ug/L and （189.50 ± 39.99 ） ug/L, respectively] were significantly decreased when compared with

关 键 词：甲状腺疾病 细胞粘着分子 放射免疫检测 

分 类 号：R686[医药卫生—骨科学]